Maternal immune activation and abnormal brain development across CNS disorders

Nature Reviews Neurology

Volumn 10, Issue 11, 2014, Pages 643-660

  Knuesel, Irene ^a   Chicha, Laurie ^b   Britschgi, Markus ^a   Schobel, Scott A ^a   Bodmer, Michael ^b   Hellings, Jessica A ^c   Toovey, Stephen ^d   Prinssen, Eric P ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c OHIO STATE UNIVERSITY   (United States)

^d Pegasus Research   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE; IMMUNOGLOBULIN; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR;

ALZHEIMER DISEASE; AUTISM; BLOOD BRAIN BARRIER; BRAIN DEVELOPMENT; BRAIN NERVE CELL; CELL MIGRATION; CENTRAL NERVOUS SYSTEM DISEASE; CEREBRAL PALSY; CLINICAL FEATURE; CYTOKINE PRODUCTION; DEVELOPMENTAL DISORDER; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; EPIGENETICS; EPILEPSY; GENETIC RISK; GENETIC TRANSCRIPTION; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOREGULATION; MATERNAL IMMUNE ACTIVATION; MICROGLIA; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NERVE CELL DIFFERENTIATION; NEUROTRANSMISSION; NONHUMAN; OUTCOME ASSESSMENT; PARKINSON DISEASE; PLASMAPHERESIS; PROTEIN DETERMINATION; PROTEIN FUNCTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; WHITE MATTER; ANIMAL; BRAIN; CENTRAL NERVOUS SYSTEM DISEASES; CHILD DEVELOPMENT DISORDERS, PERVASIVE; EMBRYOLOGY; FEMALE; IMMUNOLOGY; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL EXPOSURE;

ALZHEIMER DISEASE; ANIMALS; BRAIN; CENTRAL NERVOUS SYSTEM DISEASES; CEREBRAL PALSY; CHILD DEVELOPMENT DISORDERS, PERVASIVE; FEMALE; HUMANS; PARKINSON DISEASE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL EXPOSURE DELAYED EFFECTS; SCHIZOPHRENIA;

EID: 84908483881     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2014.187     Document Type: Review

References (264)

1. Roberts, G. W., Royston, M. C. & Götz, M. Pathology of cortical development and neuropsychiatric disorders. Ciba Found. Symp. 193, 296-321 (1995).
2. Ploeger, A., Raijmakers, M. E., van der Maas, H. L. & Galis, F. The association between autism and errors in early embryogenesis: what is the causal mechanism? Biol. Psychiatry 67, 602-607 (2010).
3. Schmidt-Kastner, R., Van, O. J., Esquivel, G., Steinbusch, H. W. & Rutten, B. P. An environmental analysis of genes associated with schizophrenia: hypoxia and vascular factors as interacting elements in the neurodevelopmental model. Mol. Psychiatry 17, 1194-1205 (2012).
4. Stiles, J. & Jernigan, T. L. The basics of brain development. Neuropsychol. Rev. 20, 327-348 (2010).
5. Atladottir, H. O. et al. Maternal infection requiring hospitalization during pregnancy and autism spectrum disorders. J. Autism Dev. Disord. 40, 1423-1430 (2010).
6. Brown, A. S. Epidemiologic studies of exposure to prenatal infection and risk of schizophrenia and autism. Dev. Neurobiol. 72, 1272-1276 (2012).
7. Fatemi, S. H., Cuadra, A. E., El-Fakahany, E. E., Sidwell, R. W. & Thuras, P. Prenatal viral infection causes alterations in nNOS expression in developing mouse brains. Neuroreport 11, 1493-1496 (2000).
8. Fatemi, S. H. et al. Prenatal viral infection leads to pyramidal cell atrophy and macrocephaly in adulthood: implications for genesis of autism and schizophrenia. Cell. Mol. Neurobiol. 22, 25-33 (2002).
9. Fatemi, S. H. et al. Defective corticogenesis and reduction in Reelin immunoreactivity in cortex and hippocampus of prenatally infected neonatal mice. Mol. Psychiatry 4, 145-154 (1999).
10. Fatemi, S. H. et al. Human influenza viral infection in utero alters glial fibrillary acidic protein immunoreactivity in the developing brains of neonatal mice. Mol. Psychiatry 7, 633-640 (2002).
11. Urakubo, A., Jarskog, L. F., Lieberman, J. A. & Gilmore, J. H. Prenatal exposure to maternal infection alters cytokine expression in the placenta, amniotic fluid, and fetal brain. Schizophr. Res. 47, 27-36 (2001).
12. Meyer, U., Feldon, J., Schedlowski, M. & Yee, B. K. Towards an immuno-precipitated neurodevelopmental animal model of schizophrenia. Neurosci. Biobehav. Rev. 29, 913-947 (2005).
13. Shi, L., Fatemi, S. H., Sidwell, R. W. & Patterson, P. H. Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring. J. Neurosci. 23, 297-302 (2003).
14. Zuckerman, L., Rehavi, M., Nachman, R. & Weiner, I. Immune activation during pregnancy in rats leads to a postpubertal emergence of disrupted latent inhibition, dopaminergic hyperfunction, and altered limbic morphology in the offspring: a novel neurodevelopmental model of schizophrenia. Neuropsychopharmacology 28, 1778-1789 (2003).
15. Meyer, U., Nyffeler, M., Yee, B. K., Knuesel, I. & Feldon, J. Adult brain and behavioral pathological markers of prenatal immune challenge during early/middle and late fetal development in mice. Brain Behav. Immun. 22, 469-486 (2008).
16. Brown, A. S. & Derkits, E. J. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am. J. Psychiatry 167, 261-280 (2010).
17. Brown, A. S. et al. Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch. Gen. Psychiatry 61, 774-780 (2004).
18. Brown, A. S. et al. Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. Am. J. Psychiatry 161, 889-895 (2004).
19. Brown, A. S. et al. Prenatal exposure to maternal infection and executive dysfunction in adult schizophrenia. Am. J. Psychiatry 166, 683-690 (2009).
20. Mednick, S. A., Machon, R. A., Huttunen, M. O. & Bonett, D. Adult schizophrenia following prenatal exposure to an influenza epidemic. Arch. Gen. Psychiatry 45, 189-192 (1988).
21. Mortensen, P. B. et al. Toxoplasma gondii as a risk factor for early-onset schizophrenia: analysis of filter paper blood samples obtained at birth. Biol. Psychiatry 61, 688-693 (2007).
22. Xiao, J. et al. Serological pattern consistent with infection with type I Toxoplasma gondii in mothers and risk of psychosis among adult offspring. Microbes Infect. 11, 1011-1018 (2009).
23. Buka, S. L., Cannon, T. D., Torrey, E. F. & Yolken, R. H. Maternal exposure to herpes simplex virus and risk of psychosis among adult offspring. Biol. Psychiatry 63, 809-815 (2008).
24. Mortensen, P. B. et al. A Danish National Birth Cohort study of maternal HSV-2 antibodies as a risk factor for schizophrenia in their offspring. Schizophr. Res. 122, 257-263 (2010).
25. Torrey, E. F., Bartko, J. J., Lun, Z. R. & Yolken, R. H. Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis. Schizophr. Bull. 33, 729-736 (2007).
26. Torrey, E. F., Bartko, J. J. & Yolken, R. H. Toxoplasma gondii and other risk factors for schizophrenia: an update. Schizophr. Bull. 38, 642-647 (2012).
27. Clarke, M. C., Tanskanen, A., Huttunen, M., Whittaker, J. C. & Cannon, M. Evidence for an interaction between familial liability and prenatal exposure to infection in the causation of schizophrenia. Am. J. Psychiatry 166, 1025-1030 (2009).
28. Nielsen, P. R., Laursen, T. M. & Mortensen, P. B. Association between parental hospital-treated infection and the risk of schizophrenia in adolescence and early adulthood. Schizophr. Bull. 39, 230-237 (2013).
29. Sorensen, H. J., Mortensen, E. L., Reinisch, J. M. & Mednick, S. A. Association between prenatal exposure to bacterial infection and risk of schizophrenia. Schizophr. Bull. 35, 631-637 (2009).
30. Brown, A. S. et al. Elevated maternal C-reactive protein and autism in a national birth cohort. Mol. Psychiatry 19, 259-264 (2014).
31. Buka, S. L. et al. Maternal cytokine levels during pregnancy and adult psychosis. Brain Behav. Immun. 15, 411-420 (2001).
32. Canetta, S. et al. Elevated maternal C-reactive protein and increased risk of schizophrenia in a national birth cohort. Am. J. Psychiatry 171, 960-968 (2014).
33. Brown, A. S. et al. Prenatal infection and cavum septum pellucidum in adult schizophrenia. Schizophr. Res. 108, 285-287 (2009).
34. Dogan, Y. et al. Intracranial ultrasound abnormalities and fetal cytomegalovirus infection: report of 8 cases and review of the literature. Fetal Diagn. Ther. 30, 141-149 (2011).
35. Ellman, L. M. et al. Structural brain alterations in schizophrenia following fetal exposure to the inflammatory cytokine interleukin-8. Schizophr. Res. 121, 46-54 (2010).
36. Bayer, T. A., Buslei, R., Havas, L. & Falkai, P. Evidence for activation of microglia in patients with psychiatric illnesses. Neurosci. Lett. 271, 126-128 (1999).
37. Radewicz, K., Garey, L. J., Gentleman, S. M. & Reynolds, R. Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics. J. Neuropathol. Exp. Neurol. 59, 137-150 (2000).
38. Upthegrove, R., Manzanares-Teson, N. & Barnes, N. M. Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis. Schizophr. Res. 155, 101-108 (2014).
39. Yamashita, Y., Fujimoto, C., Nakajima, E., Isagai, T. & Matsuishi, T. Possible association between congenital cytomegalovirus infection and autistic disorder. J. Autism Dev. Disord. 33, 455-459 (2003).
40. Abdallah, M. W. et al. Amniotic fluid chemokines and autism spectrum disorders: an exploratory study utilizing a Danish Historic Birth Cohort. Brain Behav. Immun. 26, 170-176 (2012).
41. Abdallah, M. W. et al. Amniotic fluid inflammatory cytokines: potential markers of immunologic dysfunction in autism spectrum disorders. World J. Biol. Psychiatry 14, 528-538 (2013).
42. Braunschweig, D. et al. Autism: maternally derived antibodies specific for fetal brain proteins. Neurotoxicology 29, 226-231 (2008).
43. Dalton, P. et al. Maternal neuronal antibodies associated with autism and a language disorder. Ann. Neurol. 53, 533-537 (2003).
44. Singer, H. S. et al. Antibodies against fetal brain in sera of mothers with autistic children. J. Neuroimmunol. 194, 165-172 (2008).
45. Zerbo, O. et al. Is maternal influenza or fever during pregnancy associated with autism or developmental delays? Results from the CHARGE (CHildhood Autism Risks from Genetics and Environment) study. J. Autism Dev. Disord. 43, 25-33 (2013).
46. Zerbo, O., Iosif, A. M., Delwiche, L., Walker, C. & Hertz-Picciotto, I. Month of conception and risk of autism. Epidemiology 22, 469-475 (2011).
47. Morgan, J. T. et al. Microglial activation and increased microglial density observed in the dorsolateral prefrontal cortex in autism. Biol. Psychiatry 68, 368-376 (2010).
48. Suzuki, K. et al. Microglial activation in young adults with autism spectrum disorder. JAMA Psychiatry 70, 49-58 (2013).
49. Vargas, D. L., Nascimbene, C., Krishnan, C., Zimmerman, A. W. & Pardo, C. A. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann. Neurol. 57, 67-81 (2005).
50. Chez, M. G., Dowling, T., Patel, P. B., Khanna, P. & Kominsky, M. Elevation of tumor necrosis factor-alpha in cerebrospinal fluid of autistic children. Pediatr. Neurol. 36, 361-365 (2007).
51. Pardo, C. A., Vargas, D. L. & Zimmerman, A. W. Immunity, neuroglia and neuroinflammation in autism. Int. Rev. Psychiatry 17, 485-495 (2005).
52. Parker-Athill, E. C. & Tan, J. Maternal immune activation and autism spectrum disorder: interleukin-6 signaling as a key mechanistic pathway. Neurosignals 18, 113-128 (2010).
53. Goudriaan, A. et al. Specific glial functions contribute to schizophrenia susceptibility. Schizophr. Bull. 40, 925-935 (2014).
54. Stefansson, H. et al. Common variants conferring risk of schizophrenia. Nature 460, 744-747 (2009).
55. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature 511, 421-427 (2014).
56. Voineagu, I. et al. Transcriptomic analysis of autistic brain reveals convergent molecular pathology. Nature 474, 380-384 (2011).
57. Drexhage, R. C. et al. The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. Expert Rev. Neurother. 10, 59-76 (2010).
58. Jyonouchi, H., Geng, L., Streck, D. L. & Toruner, G. A. Children with autism spectrum disorders (ASD) who exhibit chronic gastrointestinal (GI) symptoms and marked fluctuation of behavioral symptoms exhibit distinct innate immune abnormalities and transcriptional profiles of peripheral blood (PB) monocytes. J. Neuroimmunol. 238, 73-80 (2011).
59. Cardno, A. G. & Gottesman, I. I. Twin studies of schizophrenia: from bow-and-arrow concordances to star wars Mx and functional genomics. Am. J. Med. Genet. 97, 12-17 (2000).
60. Ben-David, E. & Shifman, S. Networks of neuronal genes affected by common and rare variants in autism spectrum disorders. PLoS Genet. 8, e1002556 (2012).
61. Smoller, J. W. et al. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet 381, 1371-1379 (2013).
62. Talkowski, M. E. et al. Sequencing chromosomal abnormalities reveals neurodevelopmental loci that confer risk across diagnostic boundaries. Cell 149, 525-537 (2012).
63. Fromer, M. et al. De novo mutations in schizophrenia implicate synaptic networks. Nature 506, 179-184 (2014).
64. Gulsuner, S. et al. Spatial and temporal mapping of de novo mutations in schizophrenia to a fetal prefrontal cortical network. Cell 154, 518-529 (2013).
65. Torrey, E. F., Miller, J., Rawlings, R. & Yolken, R. H. Seasonal birth patterns of neurological disorders. Neuroepidemiology 19, 177-185 (2000).
66. Sun, Y., Vestergaard, M., Christensen, J., Nahmias, A. J. & Olsen, J. Prenatal exposure to maternal infections and epilepsy in childhood: a population-based cohort study. Pediatrics 121, e1100-e1107 (2008).
67. Sun, Y., Vestergaard, M., Christensen, J. & Olsen, J. Prenatal exposure to elevated maternal body temperature and risk of epilepsy in childhood: a population-based pregnancy cohort study. Paediatr. Perinat. Epidemiol. 25, 53-59 (2011).
68. Whitehead, E. et al. Relation of pregnancy and neonatal factors to subsequent development of childhood epilepsy: a population-based cohort study. Pediatrics 117, 1298-1306 (2006).
69. Hirvonen, J. et al. Increased in vivo expression of an inflammatory marker in temporal lobe epilepsy. J. Nucl. Med. 53, 234-240 (2012).
70. During, M. J. & Spencer, D. D. Extracellular hippocampal glutamate and spontaneous seizure in the conscious human brain. Lancet 341, 1607-1610 (1993).
71. Kraguljac, N. V., Reid, M. A., White, D. M., den Hollander, J. & Lahti, A. C. Regional decoupling of N-acetyl-aspartate and glutamate in schizophrenia. Neuropsychopharmacology 37, 2635-2642 (2012).
72. Small, S. A., Schobel, S. A., Buxton, R. B., Witter, M. P. & Barnes, C. A. A pathophysiological framework of hippocampal dysfunction in ageing and disease. Nat. Rev. Neurosci. 12, 585-601 (2011).
73. Fatemi, S. H. et al. Human influenza viral infection in utero increases nNOS expression in hippocampi of neonatal mice. Synapse 29, 84-88 (1998).
74. Smith, S. E., Li, J., Garbett, K., Mirnics, K. & Patterson, P. H. Maternal immune activation alters fetal brain development through interleukin-6. J. Neurosci. 27, 10695-10702 (2007).
75. Meyer, U. Developmental neuroinflammation and schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 42, 20-34 (2013).
76. Harvey, L. & Boksa, P. Prenatal and postnatal animal models of immune activation: relevance to a range of neurodevelopmental disorders. Dev. Neurobiol. 72, 1335-1348 (2012).
77. Kneeland, R. E. & Fatemi, S. H. Viral infection, inflammation and schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 42, 35-48 (2013).
78. Meyer, U. Prenatal poly(i:C) exposure and other developmental immune activation models in rodent systems. Biol. Psychiatry 75, 307-315 (2014).
79. Meyer, U. & Feldon, J. To poly(I:C) or not to poly(I:C): advancing preclinical schizophrenia research through the use of prenatal immune activation models. Neuropharmacology 62, 1308-1321 (2012).
80. Patterson, P. H. Maternal infection and immune involvement in autism. Trends Mol. Med. 17, 389-394 (2011).
81. Malkova, N. V., Yu, C. Z., Hsiao, E. Y., Moore, M. J. & Patterson, P. H. Maternal immune activation yields offspring displaying mouse versions of the three core symptoms of autism. Brain Behav. Immun. 26, 607-616 (2012).
82. Bauman, M. D. et al. Activation of the maternal immune system during pregnancy alters behavioral development of rhesus monkey offspring. Biol. Psychiatry 75, 332-341 (2014).
83. Martin, L. A. et al. Stereotypies and hyperactivity in rhesus monkeys exposed to IgG from mothers of children with autism. Brain Behav. Immun. 22, 806-816 (2008).
84. Bauman, M. D. et al. Maternal antibodies from mothers of children with autism alter brain growth and social behavior development in the rhesus monkey. Transl. Psychiatry 3, e278 (2013).
85. Qulu, L., Daniels, W. M. & Mabandla, M. V. Exposure to prenatal stress enhances the development of seizures in young rats. Metab. Brain Dis. 27, 399-404 (2012).
86. Pineda, E. et al. Maternal immune activation promotes hippocampal kindling epileptogenesis in mice. Ann. Neurol. 74, 11-19 (2013).
87. Hawkes, C. H., Del, T. K. & Braak, H. A timeline for Parkinson's disease. Parkinsonism Relat. Disord. 16, 79-84 (2010).
88. Musiek, E. S. & Holtzman, D. M. Origins of Alzheimer's disease: reconciling cerebrospinal fluid biomarker and neuropathology data regarding the temporal sequence of amyloid-beta and tau involvement. Curr. Opin. Neurol. 25, 715-720 (2012).
89. Jacobsson, B. & Hagberg, G. Antenatal risk factors for cerebral palsy. Best Pract. Res. Clin. Obstet. Gynaecol. 18, 425-436 (2004).
90. Ribiani, E. et al. Perinatal infections and cerebral palsy. Minerva Ginecol. 59, 151-157 (2007).
91. Leviton, A. & Dammann, O. Coagulation, inflammation, and the risk of neonatal white matter damage. Pediatr. Res. 55, 541-545 (2004).
92. Nelson, K. B. & Lynch, J. K. Stroke in newborn infants. Lancet Neurol. 3, 150-158 (2004).
93. Wu, Y. W. et al. Perinatal stroke in children with motor impairment: a population-based study. Pediatrics 114, 612-619 (2004).
94. Savman, K., Heyes, M. P., Svedin, P. & Karlsson, A. Microglia/macrophage-derived inflammatory mediators galectin-3 and quinolinic acid are elevated in cerebrospinal fluid from newborn infants after birth asphyxia. Transl. Stroke Res. 4, 228-235 (2013).
95. Dammann, O. & Leviton, A. Maternal intrauterine infection, cytokines, and brain damage in the preterm newborn. Pediatr. Res. 42, 1-8 (1997).
96. Grether, J. K. & Nelson, K. B. Maternal infection and cerebral palsy in infants of normal birth weight. JAMA 278, 207-211 (1997).
97. Hagberg, H., Mallard, C. & Jacobsson, B. Role of cytokines in preterm labour and brain injury. BJOG 112 (Suppl. 1), 16-18 (2005).
98. Fleiss, B. & Gressens, P. Tertiary mechanisms of brain damage: a new hope for treatment of cerebral palsy? Lancet Neurol. 11, 556-566 (2012).
99. Ahlin, K. et al. Cerebral palsy and perinatal infection in children born at term. Obstet. Gynecol. 122, 41-49 (2013).
100. Hermansen, M. C. & Hermansen, M. G. Perinatal infections and cerebral palsy. Clin. Perinatol. 33, 315-333 (2006).
101. Andrews, W. W. et al. Early preterm birth: association between in utero exposure to acute inflammation and severe neurodevelopmental disability at 6 years of age. Am. J. Obstet. Gynecol. 198, 466-466 (2008).
102. O'Callaghan, M. E., MacLennan, A. H., Haan, E. A. & Dekker, G. The genomic basis of cerebral palsy: a HuGE systematic literature review. Hum. Genet. 126, 149-172 (2009).
103. Clouchoux, C. & Limperopoulos, C. Novel applications of quantitative MRI for the fetal brain. Pediatr. Radiol. 42 (Suppl. 1), S24-S32 (2012).
104. Girard, N. J. & Chaumoitre, K. The brain in the belly: what and how of fetal neuroimaging? J. Magn. Reson. Imaging 36, 788-804 (2012).
105. Gousias, I. S. et al. Magnetic resonance imaging of the newborn brain: automatic segmentation of brain images into 50 anatomical regions. PLoS ONE 8, e59990 (2013).
106. Shrivastava, K. et al. Temporal expression of cytokines and signal transducer and activator of transcription factor 3 activation after neonatal hypoxia/ischemia in mice. Dev. Neurosci. 35, 212-225 (2013).
107. Cai, Z., Pan, Z. L., Pang, Y., Evans, O. B. & Rhodes, P. G. Cytokine induction in fetal rat brains and brain injury in neonatal rats after maternal lipopolysaccharide administration. Pediatr. Res. 47, 64-72 (2000).
108. Larouche, A. et al. Neuronal injuries induced by perinatal hypoxic-ischemic insults are potentiated by prenatal exposure to lipopolysaccharide: animal model for perinatally acquired encephalopathy. Dev. Neurosci. 27, 134-142 (2005).
109. Paintlia, M. K., Paintlia, A. S., Barbosa, E., Singh, I. & Singh, A. K. N-acetylcysteine prevents endotoxin-induced degeneration of oligodendrocyte progenitors and hypomyelination in developing rat brain. J. Neurosci. Res. 78, 347-361 (2004).
110. Rousset, C. I. et al. Maternal exposure to LPS induces hypomyelination in the internal capsule and programmed cell death in the deep gray matter in newborn rats. Pediatr. Res. 59, 428-433 (2006).
111. Rousset, C. I. et al. Antenatal bacterial endotoxin sensitizes the immature rat brain to postnatal excitotoxic injury. J. Neuropathol. Exp. Neurol. 67, 994-1000 (2008).
112. Bell, M. J. & Hallenbeck, J. M. Effects of intrauterine inflammation on developing rat brain. J. Neurosci. Res. 70, 570-579 (2002).
113. Saadani-Makki, F. et al. Intrauterine administration of endotoxin leads to motor deficits in a rabbit model: a link between prenatal infection and cerebral palsy. Am. J. Obstet. Gynecol. 199, 651-657 (2008).
114. Stridh, L. et al. Toll-like receptor-3 activation increases the vulnerability of the neonatal brain to hypoxia-ischemia. J. Neurosci. 33, 12041-12051 (2013).
115. rd et al. Brain differences in infants at differential genetic risk for late-onset Alzheimer disease: a cross-sectional imaging study. JAMA Neurol. 71, 11-22 (2014).
116. Knickmeyer, R. C. et al. Common variants in psychiatric risk genes predict brain structure at birth. Cereb. Cortex 24, 1230-1246 (2014).
117. Braak, H. & Del Tredici, K. The pathological process underlying Alzheimer's disease in individuals under thirty. Acta Neuropathol. 121, 171-181 (2011).
118. Lambert, J. C. et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat. Genet. 41, 1094-1099 (2009).
119. Chen, L. H. et al. Polymorphisms of CR1, CLU and PICALM confer susceptibility of Alzheimer's disease in a southern Chinese population. Neurobiol. Aging 33, 210.e1-210.e7 (2012).
120. Jonsson, T. et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N. Engl. J. Med. 368, 107-116 (2013).
121. Guerreiro, R. & Hardy, J. TREM2 and neurodegenerative disease. N. Engl. J. Med. 369, 1569-1570 (2013).
122. Ray, S. et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat. Med. 13, 1369-1362 (2007).
123. Britschgi, M. et al. Modeling of pathological traits in Alzheimer's disease based on systemic extracellular signaling proteome. Mol. Cell. Proteomics 10, M111.008862 (2011).
124. Hu, W. T. et al. Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathol. 119, 669-678 (2010).
125. Bertram, L., McQueen, M. B., Mullin, K., Blacker, D. & Tanzi, R. E. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat. Genet. 39, 17-23 (2007).
126. Takahashi, K., Prinz, M., Stagi, M., Chechneva, O. & Neumann, H. TREM2-transduced myeloid precursors mediate nervous tissue debris clearance and facilitate recovery in an animal model of multiple sclerosis. PLoS Med. 4, e124 (2007).
127. Glass, C. K., Saijo, K., Winner, B., Marchetto, M. C. & Gage, F. H. Mechanisms underlying inflammation in neurodegeneration. Cell 140, 918-934 (2010).
128. Krstic, D. et al. Systemic immune challenges trigger and drive Alzheimer-like neuropathology in mice. J. Neuroinflammation 9, 151 (2012).
129. Hao, L. Y, Hao, X. Q., Li, S. H. & Li, X. H. Prenatal exposure to lipopolysaccharide results in cognitive deficits in age-increasing offspring rats. Neuroscience 166, 763-770 (2010).
130. Bilbo, S. D. Early-life infection is a vulnerability factor for aging-related glial alterations and cognitive decline. Neurobiol. Learn. Mem. 94, 57-64 (2010).
131. Bitanihirwe, B. K., Peleg-Raibstein, D., Mouttet, F., Feldon, J. & Meyer, U. Late prenatal immune activation in mice leads to behavioral and neurochemical abnormalities relevant to the negative symptoms of schizophrenia. Neuropsychopharmacology 35, 2462-2478 (2010).
132. Knuesel, I. et al. Age-related accumulation of Reelin in amyloid-like deposits. Neurobiol. Aging 30, 697-716 (2009).
133. Richetto, J., Calabrese, F, Riva, M. A. & Meyer, U. Prenatal immune activation induces maturation-dependent alterations in the prefrontal GABAergic transcriptome. Schizophr. Bull. 40, 351-361 (2013).
134. Doehner, J., Genoud, C, Imhof, C, Krstic, D. & Knuesel, I. Extrusion of misfolded and aggregated protein-a protective strategy of aging neurons? Eur. J. Neurosci. 35, 1938-1950 (2012).
135. Krstic, D. & Knuesel, I. Deciphering the mechanism underlying late-onset Alzheimer disease. Nat. Rev. Neurol. 9, 25-34 (2013).
136. Mattock, C, Marmot, M. & Stern, G. Could Parkinson's disease follow intra-uterine nfluenza? A speculative hypothesis. J. Neurol. Neurosurg. Psychiatry 51, 753-756 (1988).
137. Ebmeier, K. P. et al. Does idiopathic parkinsonism n Aberdeen follow intrauterine influenza? J. Neurol. Neurosurg. Psychiatry 52, 911-913 (1989).
138. Toovey, S., Jick, S. S. & Meier, C. R. Parkinson's disease or Parkinson symptoms following seasonal influenza. Influenza Other Respir. Viruses 5, 328-333 (2011).
139. Hardy, J., Lewis, P., Revesz, T., Lees, A. & Paisan-Ruiz, C. The genetics of Parkinson's syndromes: a critical review. Curr. Opin. Genet. Dev. 19, 254-265 (2009).
140. Lema Tome, C. M. et al. Inflammation and alpha-synuclein's prion-like behavior in Parkinson's disease-is there a link? Mol. Neurobiol. 47, 561-574 (2013).
141. Snyder-Keller, A. & Stark, P. F Prenatal nflammatory effects on nigrostriatal development in organotypic cultures. Brain Res. 1233, 160-167 (2008).
142. Carvey, P. M., Chang, Q., Lipton, J. W. & Ling, Z. Prenatal exposure to the bacteriotoxin ipopolysaccharide leads to long-term losses of dopamine neurons in offspring: a potential, new model of Parkinson's disease. Front. Biosci. 8, s826-s837 (2003).
143. Vuillermot, S. et al. Prenatal immune activation nteracts with genetic Nurr1 deficiency in the development of attentional impairments. J. Neurosci. 32, 436-451 (2012).
144. Saucedo-Cardenas, O. et al. Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons. Proc. Natl Acad. Sci. USA 95, 4013-4018 (1998).
145. Saijo, K. et al. A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell 137, 47-59 (2009).
146. Garbett, K. A., Hsiao, E. Y., Kalman, S., Patterson, P. H. & Mirnics, K. Effects of maternal immune activation on gene expression patterns in the fetal brain. Transl. Psychiatry 2, e98 (2012).
147. van Noort, J. M. et al. αβ-Crystallin is a target for adaptive immune responses and a trigger of innate responses in preactive multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 69, 694-703 (2010).
148. Braak, H., Del Tredici, K., Sandmann-Kiel, D., Rub, U. & Schultz, C. Nerve cells expressing heat-shock proteins in Parkinson's disease. Acta Neuropathol. 102, 449-454 (2001).
149. Jang, H. et al. Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration. Proc. Natl Acad. Sci. USA 106, 14063-14068 (2009).
150. Ginhoux, F. et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 330, 841-845 (2010).
151. Alliot, F., Godin, I. & Pessac, B. Microglia derive from progenitors, originating from the yolk sac, and which proliferate in the brain. Brain Res. Dev. Brain Res. 117, 145-152 (1999).
152. Hutchins, K. D., Dickson, D. W., Rashbaum, W. K. & Lyman, W. D. Localization of morphologically distinct microglial populations in the developing human fetal brain: implications for ontogeny. Brain Res. Dev. Brain Res. 55, 95-102 (1990).
153. Bhat, R. & Steinman, L. Innate and adaptive autoimmunity directed to the central nervous system. Neuron 64, 123-132 (2009).
154. Hagberg, H., Gressens, P. & Mallard, C. Inflammation during fetal and neonatal life: implications for neurologic and neuropsychiatric disease in children and adults. Ann. Neurol. 71, 444-457 (2012).
155. Aguzzi, A., Barres, B. A. & Bennett, M. L. Microglia: scapegoat, saboteur, or something else? Science 339, 156-161 (2013).
156. Boulanger, L. M. & Shatz, C. J. Immune signalling in neural development, synaptic plasticity and disease. Nat. Rev. Neurosci. 5, 521-531 (2004).
157. Marin, I. & Kipnis, J. Learning and memory and the immune system. Learn. Mem. 20, 601-606 (2013).
158. Schafer, D. P. et al. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron 74, 691-705 (2012).
159. Stevens, B. et al. The classical complement cascade mediates CNS synapse elimination. Cell 131, 1164-1178 (2007).
160. Ueno, M. & Yamashita, T. Bidirectional tuning of microglia in the developing brain: from neurogenesis to neural circuit formation. Curr. Opin. Neurobiol. 27C, 8-15 (2014).
161. Xu, D. X. et al. Tumor necrosis factor alpha partially contributes to lipopolysaccharide-induced intra-uterine fetal growth restriction and skeletal development retardation in mice. Toxicol. Lett. 163, 20-29 (2006).
162. Meyer, U. et al. Adult behavioral and pharmacological dysfunctions following disruption of the fetal brain balance between pro-inflammatory and IL-10-mediated anti-inflammatory signaling. Mol. Psychiatry 13, 208-221 (2008).
163. Hsiao, E. Y., McBride, S. W., Chow, J., Mazmanian, S. K. & Patterson, P. H. Modeling an autism risk factor in mice leads to permanent immune dysregulation. Proc. Natl Acad. Sci. USA 109, 12776-12781 (2012).
164. Zager, A., Pinheiro, M. L., Ferraz-de-Paula, V., Ribeiro, A. & Palermo-Neto, J. Increased cellmediated immunity in male mice offspring exposed to maternal immune activation during late gestation. Int. Immunopharmacol. 17, 633-637 (2013).
165. Stolp, H. B. & Dziegielewska, K. M. Review: role of developmental inflammation and blood-brain barrier dysfunction in neurodevelopmental and neurodegenerative diseases. Neuropathol. Appl. Neurobiol. 35, 132-146 (2009).
166. Theoharides, T. C., Kempuraj, D. & Redwood, L. Autism: an emerging 'neuroimmune disorder' in search of therapy. Expert Opin. Pharmacother. 10, 2127-2143 (2009).
167. Makinodan, M. et al. Maternal immune activation in mice delays myelination and axonal development in the hippocampus of the offspring. J. Neurosci. Res. 86, 2190-2200 (2008).
168. Li, Q. et al. Voxel-based analysis of postnatal white matter microstructure in mice exposed to immune challenge in early or late pregnancy. Neuroimage 52, 1-8 (2010).
169. Corriveau, R. A., Huh, G. S. & Shatz, C. J. Regulation of class I MHC gene expression in the developing and mature CNS by neural activity. Neuron 21, 505-520 (1998).
170. Glynn, M. W. et al. MHCI negatively regulates synapse density during the establishment of cortical connections. Nat. Neurosci. 14, 442-451 (2011).
171. Huh, G. S. et al. Functional requirement for class I MHC in CNS development and plasticity. Science 290, 2155-2159 (2000).
172. Stephan, A. H. et al. A dramatic increase of C1q protein in the CNS during normal aging. J. Neurosci. 33, 13460-13474 (2013).
173. Chu, Y. et al. Enhanced synaptic connectivity and epilepsy in C1q knockout mice. Proc. Natl Acad. Sci. USA 107, 7975-7980 (2010).
174. Lee, H. et al. Synapse elimination and learning rules co-regulated by MHC class I H2-Db. Nature 509, 195-200 (2014).
175. Elmer, B. M., Estes, M. L., Barrow, S. L. & McAllister, A. K. MHCI requires MEF2 transcription factors to negatively regulate synapse density during development and in disease. J. Neurosci. 33, 13791-13804 (2013).
176. Ozawa, K. et al. Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: a neurodevelopmental animal model of schizophrenia. Biol. Psychiatry 59, 546-554 (2006).
177. Romero, E., Guaza, C., Castellano, B. & Borrell, J. Ontogeny of sensorimotor gating and immune impairment induced by prenatal immune challenge in rats: implications for the etiopathology of schizophrenia. Mol. Psychiatry 15, 372-383 (2010).
178. Dalton, V. S., Verdurand, M., Walker, A., Hodgson, D. M. & Zavitsanou, K. Synergistic effect between maternal infection and adolescent cannabinoid exposure on serotonin 5HT1A receptor binding in the hippocampus: testing the "two hit" hypothesis for the development of schizophrenia. ISRN Psychiatry 2012, 451865 (2012).
179. Lin, Y. L., Lin, S. Y. & Wang, S. Prenatal lipopolysaccharide exposure increases anxietylike behaviors and enhances stress-induced corticosterone responses in adult rats. Brain Behav. Immun. 26, 459-468 (2012).
180. Nouel, D., Burt, M., Zhang, Y., Harvey, L. & Boksa, P. Prenatal exposure to bacterial endotoxin reduces the number of GAD67-and reelin-immunoreactive neurons in the hippocampus of rat offspring. Eur. Neuropsychopharmacol. 22, 300-307 (2012).
181. A receptor immunoreactivity in the adult offspring: implications for schizophrenia. Neuroscience 143, 51-62 (2006).
182. Roumier, A. et al. Prenatal activation of microglia induces delayed impairment of glutamatergic synaptic function. PLoS ONE 3, e2595 (2008).
183. Leviton, A. & Gressens, P. Neuronal damage accompanies perinatal white-matter damage. Trends Neurosci. 30, 473-478 (2007).
184. Meyer, U. et al. The time of prenatal immune challenge determines the specificity of inflammation-mediated brain and behavioral pathology. J. Neurosci. 26, 4752-4762 (2006).
185. Oskvig, D. B., Elkahloun, A. G., Johnson, K. R., Phillips, T. M. & Herkenham, M. Maternal immune activation by LPS selectively alters specific gene expression profiles of interneuron migration and oxidative stress in the fetus without triggering a fetal immune response. Brain Behav. Immun. 26, 623-634 (2012).
186. Folsom, T. D. & Fatemi, S. H. The involvement of Reelin in neurodevelopmental disorders. Neuropharmacology 68, 122-135 (2013).
187. Knuesel, I. Reelin-mediated signaling in neuropsychiatric and neurodegenerative diseases. Prog. Neurobiol. 91, 257-274 (2010).
188. Fatemi, S. H., Stary, J. M. & Egan, E. A. Reduced blood levels of reelin as a vulnerability factor in pathophysiology of autistic disorder. Cell. Mol. Neurobiol. 22, 139-152 (2002).
189. Haas, C. A. & Frotscher, M. Reelin deficiency causes granule cell dispersion in epilepsy. Exp. Brain Res. 200, 141-149 (2010).
190. Chin, J. et al. Reelin depletion in the entorhinal cortex of human amyloid precursor protein transgenic mice and humans with Alzheimer's disease. J. Neurosci. 27, 2727-2733 (2007).
191. Fatemi, S. H., Pearce, D. A., Brooks, A. I. & Sidwell, R. W. Prenatal viral infection in mouse causes differential expression of genes in brains of mouse progeny: a potential animal model for schizophrenia and autism. Synapse 57, 91-99 (2005).
192. Connor, C. M. et al. Maternal immune activation alters behavior in adult offspring, with subtle changes in the cortical transcriptome and epigenome. Schizophr. Res. 140, 175-184 (2012).
193. Tang, B., Jia, H., Kast, R. J. & Thomas, E. A. Epigenetic changes at gene promoters in response to immune activation in utero. Brain Behav. Immun. 30, 168-175 (2013).
194. Pickett, J. Current investigations in autism brain tissue research. J. Autism Dev. Disord. 31, 521-527 (2001).
195. Martins-de-Souza, D. et al. Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia. J. Psychiatr. Res. 44, 1176-1189 (2010).
196. Renkawek, K., Voorter, C. E., Bosman, G. J., van Workum, F. P. & de Jong, W. W. Expression of alpha B-crystallin in Alzheimer's disease. Acta Neuropathol. 87, 155-160 (1994).
197. Perry, V. H. & Holmes, C. Microglial priming in neurodegenerative disease. Nat. Rev. Neurol. 10, 217-224 (2014).
198. Zhang, Z., Trautmann, K. & Schluesener, H. J. Microglia activation in rat spinal cord by systemic injection of TLR3 and TLR7/8 agonists. J. Neuroimmunol. 164, 154-160 (2005).
199. Giovanoli, S. et al. Stress in puberty unmasks latent neuropathological consequences of prenatal immune activation in mice. Science 339, 1095-1099 (2013).
200. Juckel, G. et al. Microglial activation in a neuroinflammational animal model of schizophrenia -a pilot study. Schizophr. Res. 131, 96-100 (2011).
201. Abazyan, B. et al. Prenatal interaction of mutant DISC1 and immune activation produces adult psychopathology. Biol. Psychiatry 68, 1172-1181 (2010).
202. Lipina, T. V., Zai, C., Hlousek, D., Roder, J. C. & Wong, A. H. Maternal immune activation during gestation interacts with Disc1 point mutation to exacerbate schizophrenia-related behaviors in mice. J. Neurosci. 33, 7654-7666 (2013).
203. Ehninger, D. et al. Gestational immune activation and Tsc2 haploinsufficiency cooperate to disrupt fetal survival and may perturb social behavior in adult mice. Mol. Psychiatry 17, 62-70 (2012).
204. Burt, M. A., Tse, Y. C., Boksa, P. & Wong, T. P. Prenatal immune activation interacts with stress and corticosterone exposure later in life to modulate N-methyl-d-aspartate receptor synaptic function and plasticity. Int. J. Neuropsychopharmacol. 16, 1835-1848 (2013).
205. Deslauriers, J., Larouche, A., Sarret, P. & Grignon, S. Combination of prenatal immune challenge and restraint stress affects prepulse inhibition and dopaminergic/GABAergic markers. Prog. Neuropsychopharmacol. Biol. Psychiatry 45, 156-164 (2013).
206. Suvisaari, J. M., Haukka, J. K., Tanskanen, A. J. & Lonnqvist, J. K. Decline in the incidence of schizophrenia in Finnish cohorts born from 1954 to 1965. Arch. Gen. Psychiatry 56, 733-740 (1999).
207. Rook, G. A., Raison, C. L. & Lowry, C. A. Microbiota, immunoregulatory old friends and psychiatric disorders. Adv. Exp. Med. Biol. 817, 319-356 (2014).
208. Cono, J., Cragan, J. D., Jamieson, D. J. & Rasmussen, S. A. Prophylaxis and treatment of pregnant women for emerging infections and bioterrorism emergencies. Emerg. Infect. Dis. 12, 1631-1637 (2006).
209. O'Grady, K. A. et al. FluMum: a prospective cohort study of mother-infant pairs assessing the effectiveness of maternal influenza vaccination in prevention of influenza in early infancy. BMJ Open 4, e005676 (2014).
210. Trotta, F. et al. Evaluation of safety of A/H1N1 pandemic vaccination during pregnancy: cohort study. BMJ 348, g3361 (2014).
211. Cleary, B. J., Rice, U., Eogan, M., Metwally, N. & McAuliffe, F. 2009 A/H1N1 influenza vaccination in pregnancy: uptake and pregnancy outcomes-a historical cohort study. Eur. J. Obstet. Gynecol. Reprod. Biol. 178, 163-168 (2014).
212. Nahmias, A. J., Nahmias, S. B. & Danielsson, D. The possible role of transplacentally-acquired antibodies to infectious agents, with molecular mimicry to nervous system sialic acid epitopes, as causes of neuromental disorders: prevention and vaccine implications. Clin. Dev. Immunol. 13, 167-183 (2006).
213. Brown, A. S. & Patterson, P. H. Maternal infection and schizophrenia: implications for prevention. Schizophr. Bull. 37, 284-290 (2011).
214. Cervantes-Gonzalez, M. & Launay, O. Pandemic influenza A (H1N1) in pregnant women: impact of early diagnosis and antiviral treatment. Expert Rev. Anti Infect.Ther. 8, 981-984 (2010).
215. Petersen, I., Gilbert, R., Evans, S., Ridolfi, A. & Nazareth, I. Oral antibiotic prescribing during pregnancy in primary care: UK population-based study. J. Antimicrob. Chemother. 65, 2238-2246 (2010).
216. Wollenhaupt, M., Chandrasekaran, A. & Tomianovic, D. The safety of oseltamivir in pregnancy: an updated review of post-marketing data. Pharmacoepidemiol. Drug Saf. http:// dx.doi.org/10.1002/pds.3673.
217. Beau, A. B. et al. Safety of oseltamivir during pregnancy: a comparative study using the EFEMERIS database. BJOG 121, 895-900 (2014).
218. Jamieson, D. J. et al. H1N1 2009 influenza virus infection during pregnancy in the USA. Lancet 374, 451-458 (2009).
219. Treatment of influenza during pregnancy. US Food and Drug Administration [online], http://www. fda.gov/drugs/drugsafety/ informationbydrugclass/ucm184917.htm ( 2009).
220. Parker-Athill, E. et al. Flavonoids, a prenatal prophylaxis via targeting JAK2/STAT3 signaling to oppose IL-6/MIA associated autism. J. Neuroimmunol. 217, 20-27 (2009).
221. Chicha, L., Smith, T. & Guzman, R. Stem cells for brain repair in neonatal hypoxia-ischemia. Childs Nerv. Syst. 30, 37-46 (2014).
222. Miller, B. J., Buckley, P., Seabolt, W., Mellor, A. & Kirkpatrick, B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 70, 663-671 (2011).
223. Aberg, K. A. et al. Methylome-wide association study of schizophrenia: identifying blood biomarker signatures of environmental insults. JAMA. Psychiatry 71, 255-264 (2014).
224. Llano, D. A., Devanarayan, V. & Simon, A. J. Evaluation of plasma proteomic data for Alzheimer disease state classification and for the prediction of progression from mild cognitive impairment to Alzheimer disease. Alzheimer Dis. Assoc. Disord. 27, 233-243 (2013).
225. Kim, S. et al. Influence of genetic variation on plasma protein levels in older adults using a multi-analyte panel. PLoS ONE 8, e70269 (2013).
226. Busse, S. et al. Different distribution patterns of lymphocytes and microglia in the hippocampus of patients with residual versus paranoid schizophrenia: further evidence for disease course-related immune alterations? Brain Behav. Immun. 26, 1273-1279 (2012).
227. Doorduin, J. et al. Neuroinflammation in schizophrenia-related psychosis: a PET study. J. Nucl. Med. 50, 1801-1807 (2009).
228. 11C]PK11195 positron emission tomography study. Biol. Psychiatry 64, 820-822 (2008).
229. 11C-(R)-PK11195. J. Psychopharm. 28 (Suppl.), A47 (2014).
230. 11C]DAA1106. Int. J. Neuropsychopharmacol. 13, 943-950 (2010).
231. Sommer, I. E. et al. Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr. Bull. 40, 181-191 (2014).
232. Zavitsanou, K. et al. Effect of maternal immune activation on the kynurenine pathway in preadolescent rat offspring and on MK801-nduced hyperlocomotion in adulthood: amelioration by COX-2 inhibition. Brain Behav. Immun. http://dx.doi.org/10.1016/ j.bbi.2014.05.011.
233. Mattei, D. et al. Minocycline rescues decrease in neurogenesis, increase in microglia cytokines and deficits in sensorimotor gating in an animal model of schizophrenia. Brain Behav. Immun. http://dx.doi.org/10.1016/j.bbi.2014.01.019.
234. Ozkara, C. & Vigevano, F. Immuno-and antiinflammatory therapies in epileptic disorders. Epilepsia 52 (Suppl. 3), 45-51 (2011).
235. Vlad, S. C, Miller, D. R., Kowall, N. W. & Felson, D. T. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 70, 1672-1677 (2008).
236. Chen, H. et al. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann. Neurol. 58, 963-967 (2005).
237. McGeer, P. L, Schulzer, M. & McGeer, E. G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 47, 425-432 (1996).
238. Hoozemans, J. J. & O'Banion, M. K. The role of COX-1 and COX-2 in Alzheimer's disease pathology and the therapeutic potentials of nonsteroidal anti-inflammatory drugs. Curr. Drug Targets CNS Neurol. Disord. 4, 307-315 (2005).
239. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/ NCT01701089 ( 2014).
240. Butovsky, O. et al. Identification of a unique TGF-ß-dependent molecular and functional signature in microglia. Nat. Neurosci. 17, 131-143 (2014).
241. Figuera-Losada, M., Rojas, C. & Slusher, B. S. nhibition of microglia activation as a phenotypic assay in early drug discovery. J. Biomol. Screen. 19, 17-31 (2013).
242. Tabas, I. & Glass, C. K. Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science 339, 166-172 (2013).
243. Andersen, S. L. Trajectories of brain development: point of vulnerability or window of opportunity? Neurosci. Biobehav. Rev. 27, 3-18 (2003).
244. Bhugra, D. The global prevalence of schizophrenia. PLoS Med. 2, e151 (2005).
245. Tandon, R. et al. Definition and description of schizophrenia in the DSM-5. Schizophr. Res. 150, 3-10 (2013).
246. Lauritsen, M. B. Autism spectrum disorders. Eur. Child. Adolesc. Psychiatry 22 (Suppl. 1), S37-S42 (2013).
247. Ronald, A. & Hoekstra, R. A. Autism spectrum disorders and autistic traits: a decade of new twin studies. Am. J. Med. Genet. B Neuropsychiatr. Genet. 156B, 255-274 (2011).
248. Righini, A. et al. Diffusion tensor imaging of early changes in corpus callosum after acute cerebral hemisphere lesions in newborns. Neuroradiology 52, 1025-1035 (2010).
249. Hauser, W. A. The prevalence and incidence of convulsive disorders in children. Epilepsia 35 (Suppl. 2), S1-S6 (1994).
250. th edn (eds Batshaw, M. L. et al.) 439-460 (Brookes Publishing Co., 2007).
251. Kurtz, Z., Tookey, P. & Ross, E. Epilepsy in young people: 23 year follow up of the British national child development study. BMJ 316, 339-342 (1998).
252. Theoharides, T. C. & Zhang, B. Neuro-inflammation, blood-brain barrier, seizures and autism. J. Neuroinflammation 8, 168 (2011).
253. Hankins, G. D. & Speer, M. Defining the pathogenesis and pathophysiology of neonatal encephalopathy and cerebral palsy. Obstet. Gynecol. 102, 628-636 (2003).
254. Nelson, K. B. The epidemiology of cerebral palsy in term infants. Ment. Retard. Dev. Disabil. Res. Rev. 8, 146-150 (2002).
255. Leviton, A. et al. The relationship between early concentrations of 25 blood proteins and cerebral white matter injury in preterm newborns: the ELGAN study. J. Pediatr. 158, 897-903 (2011).
256. Mann, J. R., McDermott, S., Bao, H. & Bersabe, A. Maternal genitourinary infection and risk of cerebral palsy. Dev. Med. Child Neurol. 51, 282-288 (2009).
257. Patrick, L. A. & Smith, G. N. Proinflammatory cytokines: a link between chorioamnionitis and fetal brain injury. J. Obstet. Gynaecol. Can. 24, 705-709 (2002).
258. Nagae, L. M. et al. Diffusion tensor imaging in children with periventricular leukomalacia: variability of injuries to white matter tracts. AJNR Am. J. Neuroradiol. 28, 1213-1222 (2007).
259. Ferri, C. P. et al. Global prevalence of dementia: a Delphi consensus study. Lancet 366, 2112-2117 (2005).
260. Castellani, R. J., Rolston, R. K. & Smith, M. A. Alzheimer disease. Dis. Mon. 56, 484-546 (2010).
261. Serrano-Pozo, A., Frosch, M. P., Masliah, E. & Hyman, B. T. Neuropathological alterations in Alzheimer disease. Cold Spring Harb. Perspect. Med. 1, a006189 (2011).
262. Berg, D. et al. Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. Lancet Neurol. 12, 514-524 ( 2013).
263. Dickson, D. W. et al. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol. 8, 1150-1157 (2009).
264. Goedert, M., Spillantini, M. G., Del, T. K. & Braak, H. 100 years of Lewy pathology. Nat. Rev. Neurol. 9, 13-24 (2013).